[Author note — replace with real first-hand credibility, e.g. “I’ve written and reviewed ad copy and landing pages for research peptide brands across the US and UK for X years. This is the framework we apply to every page before it goes live.”] The paragraphs below are publish-ready; only the bracketed author details and any brand-specific examples need your input.
The fastest way to lose a peptide brand’s website — its ad accounts, its payment processor, sometimes the domain itself — is a single sentence that says the wrong thing. Not a bad product. Not weak SEO. A claim. In a category this heavily scrutinised, what your site says is a compliance decision before it’s a marketing one, and most brands only learn where the line sits after they’ve crossed it.
This guide draws that line clearly for both major markets: the United States, where the FTC and FDA set the terms, and the United Kingdom, where the ASA/CAP Code and the MHRA do. It is written for research-use-only (RUO) peptide brands. It is not legal advice — it’s the practical standard a specialist applies, and the point where you should bring in qualified counsel.
The one principle everything follows from: a research-use-only product is sold for laboratory research, not for human use. Every word on your site must be consistent with that. The moment your copy implies a person will take the compound — to lose weight, heal, build muscle, sleep, or anything else — you have left the RUO lane and entered drug-marketing territory you are not licensed for.
What your site cannot say
These are the categories of claim that move a page from “research supplier” to “unapproved drug marketer” in the eyes of regulators and ad platforms alike:
- Health or therapeutic claims. Anything stating or implying the product treats, prevents, heals, or improves a condition — “supports fat loss,” “accelerates recovery,” “improves skin.” In the US these are exactly the claims the FDA and FTC act on; in the UK they trigger ASA rulings and MHRA interest.
- Dosage or administration guidance. Reconstitution instructions framed for human use, “recommended dosage,” cycle lengths, injection guidance. Dosing language is one of the clearest signals of intended human consumption.
- Testimonials about effects. Reviews describing how someone felt or what results they saw are human-use claims in disguise — and you’re responsible for them even when a customer wrote them.
- Before-and-after or results imagery. Physique photos, progress charts, “my results” content. Powerful marketing, direct violation.
- Comparisons to approved drugs. “Like [brand-name drug] but…” invites the strictest category of scrutiny in both markets.
What your site can say
The RUO lane is narrower, but it is real, and brands operate in it successfully every day:
- Product identity and specification. Compound name, sequence, molecular weight, purity, form. Factual, verifiable, non-promotional.
- Quality and testing evidence. Certificates of analysis, third-party purity testing, batch data, storage and handling information. This is where RUO brands should compete — and where trust is actually won.
- Research-use framing, stated plainly. Clear “For Research Use Only. Not for Human Consumption.” labelling, and copy that consistently addresses a research audience.
- Logistics and service. Shipping, handling, payment, support, returns — the operational facts a lab buyer needs.
The tell that you’ve crossed the line: read any sentence and ask “who is the subject — a researcher, or a person taking this?” If the implied subject is someone consuming the compound, rewrite it. This single test catches the large majority of violations before they publish.
US vs UK: the differences that matter
The principle is shared, but enforcement differs. In the US, the FDA treats many peptides as unapproved new drugs and the FTC polices deceptive health claims — action tends to follow marketing that promotes human use, and penalties are substantial. In the UK, the ASA rules on advertising claims (and rulings are public), while the MHRA governs whether a product is an unlicensed medicine; the CAP Code also restricts how even legitimate products can be advertised to the public. A brand selling into both markets has to satisfy the stricter reading of each, not the more convenient one.
Why this is a marketing advantage, not just a constraint
Here’s what most agencies in this space miss: rigorous compliance is a competitive moat. Sites that drift into health claims are one complaint away from disruption, which caps how much any brand can safely invest in them. A brand whose entire presence holds the RUO line can advertise, rank and scale with far less risk — and can say so. “Compliant by design” is a stronger promise to a serious brand owner than any growth-hack, because they’ve usually already been burned by the alternative.
A practical pre-publish checklist
- Every page carries clear RUO labelling.
- No health, therapeutic, dosage, or administration claims anywhere — including FAQs, meta descriptions, and alt text.
- No effect-based testimonials or before/after content.
- Ad copy and its landing page hold the same line (reviewers check both).
- Claims about purity and testing are accurate and backed by real documents.
- For anything ambiguous — a specific compound’s status, a borderline phrase — qualified counsel has reviewed it before scale.
The disclaimer that matters
We’re marketers, not lawyers, and regulatory status varies by compound and changes over time. This framework is how we keep RUO brands on the right side of the line in day-to-day marketing; it is not a substitute for legal advice. For any product whose status is unclear, or before scaling spend in a new market, have qualified counsel review your specific pages and claims.